Molecular Mechanisms and Biomarkers in Parkinson's Disease

Parkinson’s Disease arises from progressive degeneration of dopaminergic neurons in the substantia nigra leading to motor and non-motor symptoms. Molecular hallmarks include accumulation of misfolded alpha-synuclein, mitochondrial dysfunction, impaired protein clearance and neuroinflammatory responses. Genetic factors encompass rare familial mutations and common risk variants that converge on pathways of vesicular trafficking, mitochondrial homeostasis and oxidative stress. Biomarkers under investigation range from fluid markers—such as phosphorylated alpha-synuclein in cerebrospinal fluid or peripheral blood transcriptomic signatures—to imaging markers of nigrostriatal integrity. Recent advances in single-cell transcriptomics and spatial profiling have resolved cell-type specific vulnerabilities, revealing subpopulations of dopaminergic neurons with distinct regulatory programmes and resilience profiles. Integration of multi-omics datasets now underpins efforts to identify early diagnostic indicators and therapeutic targets, with the ultimate aim of personalised intervention to halt or reverse neurodegeneration.

Research from Nature Portfolio

Recent studies have delineated discrete neuronal subtypes within the human substantia nigra that exhibit differential vulnerability in Parkinson’s Disease. Single-cell genomic profiling identified a subset of dopaminergic neurons marked by AGTR1 expression in the ventral tier, which is selectively depleted in patients and enriched for p53-mediated stress pathways and genetic risk loci; this advances understanding of cell-intrinsic degeneration mechanisms. Complementary work using a primate model of parkinsonism resolved seven transcriptionally defined dopaminergic neuron subtypes along a gradient of susceptibility, linking resilience to a FOXP2-centred regulatory network conserved across species and revealing concurrent glial immune activation in the nigrostriatal circuit. These resources furnish a detailed molecular atlas to guide biomarker discovery and cell-type targeted therapies.

Molecular Mechanisms and Biomarkers in Parkinson's Disease publication trend

The graph below shows the total number of articles in molecular mechanisms and biomarkers in parkinson's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Alpha-synuclein: A neuronal protein prone to misfolding and aggregation into Lewy bodies, central to Parkinson’s pathology.

Dopaminergic neuron: A nerve cell that synthesises and releases dopamine, predominantly located in the substantia nigra.

Substantia nigra: A midbrain region critical for motor control and the primary site of dopaminergic neuron loss in Parkinson’s Disease.

Transcriptomics: The study of the complete set of RNA transcripts produced by the genome, used to profile gene expression changes.

Single-cell RNA sequencing: A technique to measure gene expression in individual cells, enabling identification of distinct cellular subpopulations.

Biomarker: A measurable indicator of disease state or progression, used for diagnosis or monitoring therapeutic response.

Neuroinflammation: Activation of the central nervous system’s immune cells, contributing to neuronal damage in neurodegenerative disorders.

References

1. Unravelling cell type-specific responses to Parkinson’s Disease at single cell resolution. Molecular Neurodegeneration (2024).
2. A primate nigrostriatal atlas of neuronal vulnerability and resilience in a model of Parkinson’s disease. Nature Communications (2023).
3. Transcriptomic profiling of Parkinson's disease brains reveals disease stage specific gene expression changes. Acta Neuropathologica (2023).
4. Systems level analysis of sex-dependent gene expression changes in Parkinson’s disease. npj Parkinson's Disease (2023).
5. Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson’s disease. Nature Neuroscience (2022).